VTRS

LONG

VIATRIS INC

Funds

Score

4.50

vs SPY

+4.9%

Stock return (since Q-end)

+21.2%

SPY return (since Q-end)

+16.3%

Current price

$16.26

News Summary

Neutral

Viatris delivered a strong Q1 2026 earnings beat (EPS $0.59 vs. $0.51 forecast) with 8% YoY revenue growth and reaffirmed full-year guidance, while executing a major $650M cost-reduction restructuring targeting 10% workforce reduction. However, operating cash flow declined 27% YoY, gross margin compressed significantly on a GAAP basis, the CFO departed unexpectedly, and ongoing FDA concerns at key manufacturing facilities present material execution risks.

Red flags

•Operating cash flow declined 27% YoY to $388M despite revenue growth—signals operational efficiency concerns
•GAAP gross margin compressed 280 basis points (35.7% to 32.9%) despite favorable mix, indicating cost pressures
•CFO departure (May 4, 2026) with interim replacement—leadership instability during restructuring execution
•FDA warning and import alert on Indore manufacturing facility—regulatory/operational risk to supply chain
•10% global workforce reduction underway—execution risk on $650M cost-savings target and reinvestment quality

Funds Buying (3)

Fund	Manager	Shares Held	∆ Shares	Position Value	QoQ	Status
Glenview Capital	Larry Robbins	9.1M	+9.1M	$122.8B	—	NEW
Greenlight Capital	David Einhorn	1.8M	+1.8M	$24.6B	—	NEW
Point72	Steve Cohen	1.8M	+1.8M	$24.0B	—	NEW

Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter.